Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients

Reduced activity of cholesterol 7α‐hydroxylase

Dagny Ståhlberg, Eva Reihnér, Mats Rudling, Lars Berglund, Kurt Einarsson, Bo Angelin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7α‐hydroxylasé activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)

Original languageEnglish (US)
Pages (from-to)1025-1030
Number of pages6
JournalHepatology
Volume21
Issue number4
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Bezafibrate
Gallstones
Cholesterol
Liver
Bile
Sterol O-Acyltransferase
Lipoprotein Receptors
Hydroxymethylglutaryl CoA Reductases
Fibric Acids
Therapeutics
Cholecystectomy
Coenzyme A
Triglycerides
Biopsy
Enzymes

ASJC Scopus subject areas

  • Hepatology

Cite this

Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients : Reduced activity of cholesterol 7α‐hydroxylase. / Ståhlberg, Dagny; Reihnér, Eva; Rudling, Mats; Berglund, Lars; Einarsson, Kurt; Angelin, Bo.

In: Hepatology, Vol. 21, No. 4, 1995, p. 1025-1030.

Research output: Contribution to journalArticle

Ståhlberg, Dagny ; Reihnér, Eva ; Rudling, Mats ; Berglund, Lars ; Einarsson, Kurt ; Angelin, Bo. / Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients : Reduced activity of cholesterol 7α‐hydroxylase. In: Hepatology. 1995 ; Vol. 21, No. 4. pp. 1025-1030.
@article{5d9001f3b2ca4f92a9c3f9aff3031b59,
title = "Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α‐hydroxylase",
abstract = "Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30{\%} and 37{\%}, respectively. The hepatic cholesterol 7α‐hydroxylas{\'e} activity was reduced by ≈60{\%} in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)",
author = "Dagny St{\aa}hlberg and Eva Reihn{\'e}r and Mats Rudling and Lars Berglund and Kurt Einarsson and Bo Angelin",
year = "1995",
doi = "10.1002/hep.1840210421",
language = "English (US)",
volume = "21",
pages = "1025--1030",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients

T2 - Reduced activity of cholesterol 7α‐hydroxylase

AU - Ståhlberg, Dagny

AU - Reihnér, Eva

AU - Rudling, Mats

AU - Berglund, Lars

AU - Einarsson, Kurt

AU - Angelin, Bo

PY - 1995

Y1 - 1995

N2 - Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7α‐hydroxylasé activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)

AB - Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7α‐hydroxylasé activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)

UR - http://www.scopus.com/inward/record.url?scp=84991145406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991145406&partnerID=8YFLogxK

U2 - 10.1002/hep.1840210421

DO - 10.1002/hep.1840210421

M3 - Article

VL - 21

SP - 1025

EP - 1030

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -